Chest pain: When conventional treatments don't work
April 19, 2012 By Anjum Nayyar in Cardiology
Chronic chest pain affects approximately half a million Canadians. Credit: Bigstock photo
Tens of thousands of Canadians seek emergency services and are referred for angiograms each year to investigate sources of chest pain. For approximately half a million Canadians, chronic chest pain or, specifically, refractory angina is a devastating disease. Refractory angina is not only painful but is also frightening and debilitating. There have been no specific Canadian guidelines for treating this population until now. Thanks to the joint research at U of T and McMaster, new guidelines will help provide feasible options for cardiac pain management for patients suffering from refractory angina. Writer Anjum Nayyar spoke with researcher and professor of nursing Michael McGillion about the new guidelines.
Why was it necessary to draft new chest pain guidelines?
These are refractory angina guidelines. People who have this kind of chronic angina dont respond to conventional treatments for heart disease. They have a chest pain problem that continues despite maximal medical therapy: traditional medications, bypass surgery, nitrate therapy these treatments dont work for them. These patients really become a specialized group, and there were no specific guidelines for treating this kind of population. And as with other forms of chronic pain, chronic pain mechanisms can kick in for these patients. The guidelines are really about combining the efforts from a cardiology point of view and also from a chronic pain-related treatment point of view.
How do the new guidelines change the way doctors will treat and diagnose chest pain?
The guidelines bring together approaches that would not typically be conventional in cardiology. These patients typically fall through the cracks sometimes theyre called no option angina, but calling them no option is really not helpful, so our first recommendation is that this condition be recognized as refractory angina. Even if weve done our duty in terms of addressing the heart disease, these patients have a real physiological problem with their chest pain. One of the recommendations we make is that cardiovascular experts and pain experts work together on joint assessments to treat these patients. Then its really about understanding the ischemic and neural pain mechanisms involved. The key message is weve got to understand these patients from both lenses. Traditionally those two worlds have not formally worked together.
How common is refractory angina?
We know in the US it affects between 600,000 and 1.8 million people with 50,000 cases a year. And in continental Europe, there are between 30,000 and 50,000 new cases a year as well. In Canada we dont have the right tracking system for refractory angina as yet but data from the Canadian Community Health Survey tell us that we have about 500,000 people that live with unresolved angina. A good portion of those people are likely to have this problem. We know, for example, that up to 50% of patients who undergo angioplasty or bypass surgery for heart disease can end up with a recurrent chest pain problem.
What are some of the biggest misconceptions about angina?
One of the biggest misconceptions is that the pain is not real. Its actually quite devastating because every time a person has it, higher brain centres tell them that they are in danger. Its very debilitating when this experience is chronic.
How will the new guidelines influence future clinical practice and research in this area?
We point out the gaps in research. One of the key recommendations we make is that there be specialized centres to have a combined system of training. We know now of the most promising direction for some people. We know, for example, that spinal cord stimulation is really quite effective to improve functional status for many. But we need policy because its a highly specialized approach. A less resource-intensive approach is cognitive self-management training. This approach is effective for helping people with refractory angina to be less afraid and more functional, but its currently not routinely available.
Provided by
University of Toronto
-
Chest pain med is effective for refractory angina, but adherence problematic
Apr 04, 2011 |
not rated yet |
0
-
Study examines prevalence of chest pain in patients 1 year after heart attack
Jun 23, 2008 |
not rated yet |
0
-
Heart study shows many suffer poor quality of life
Sep 15, 2009 |
not rated yet |
0
-
Unexplained chest pain can be due to stress
Feb 09, 2009 |
not rated yet |
0
-
Heart disease study highlights Scottish ethnic groups most at risk
Dec 21, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
The Durability of Bone: Long Falls
7 hours ago
-
Is energy convertible to matter?
8 hours ago
-
Rotating electron as a dipole is this right?
11 hours ago
-
Dipole term in multipole expansion
15 hours ago
-
Bubbles in a Pre-Boiling/Boiling pot of water
16 hours ago
-
Assumptions of Griffith's fracture theory
May 21, 2013
- More from Physics Forums - Classical Physics
More news stories
Biodegradable stent proves non-inferior to drug-eluting stent
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...
Cardiology
11 hours ago |
5 / 5 (1) |
0
Post-approval TAVI registry shows high rates of device success at one year
One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries to-date – reported today at EuroPCR 2013 show good clinical outcomes in routine clinical practice, ...
Cardiology
11 hours ago |
not rated yet |
0
Antidepressant reduces stress-induced heart condition
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
Cardiology
12 hours ago |
5 / 5 (1) |
0
|
Study identifies superior hypertension treatment, efficacy between sexes
(Medical Xpress)—In a recent subgroup analysis of the largest blood pressure treatment trial in history, University of Alabama at Birmingham (UAB) researchers found that women and men react the same to ...
Cardiology
20 hours ago |
5 / 5 (1) |
0
Evaluating a new way to open clogged arteries
Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments ...
Cardiology
21 hours ago |
4.7 / 5 (6) |
0
|
Phthalates: Study links chemicals widely found in plastics, processed food to elevated blood pressure in children, teens
Plastic additives known as phthalates (pronounced THAL-ates) are odorless, colorless and just about everywhere: They turn up in flooring, plastic cups, beach balls, plastic wrap, intravenous tubing and—according to the ...
If you can remember it, you can remember it wrong
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
B vitamins could delay dementia
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
Insight into the dazzling impact of insulin in cells
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
New sleeping pill poised to hit US markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Reducing caloric intake delays nerve cell loss
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...